Premium
Dose‐response effects of pentoxifylline on erythrocyte filterability: Clinical and animal model studies
Author(s) -
Ambrus Julian L,
Anain Joseph M,
Anain Shirley M,
Anain Paul M,
Anain Joseph M,
Stadler Steven,
Brobst Joyce A,
Cobert Barton L,
Savitsky J Philip
Publication year - 1990
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1990.117
Subject(s) - pentoxifylline , medicine , placebo , metabolite , dose , red blood cell , red cell , pharmacology , active metabolite , pharmacokinetics , oral administration , pathology , alternative medicine
Ten patients with chronic occlusive arteriosclerosis received single oral doses of 100, 200, 400, 800, and 1200 mg pentoxifylline in a single‐blind, placebo‐controlled study. Blood samples were drawn at baseline and at 2 hour intervals for 6 hours. Drug and metabolite levels, as well as red cell filterability (deformability), were determined on all blood samples. Statistically significant dose‐response increases of red cell filterability were found 4 and 6 hours after oral medication with the dosages of 200 to 1200 mg pentoxifylline. These changes were proportional to the plasma levels of pentoxifylline and metabolites 1 and 5 of this agent. Attempts were made to develop a suitable animal‐screening method for agents with similar activity and to determine whether red blood cells in the absence of disease‐related abnormalities may respond to this type of therapy. Five healthy Macaca arctoides monkeys were given 24 mg/kg pentoxifylline intravenously, and measurable but lesser increases in red cell deformability were recorded than in the patients. Clinical Pharmacology and Therapeutics (1990) 48, 50–56; doi: 10.1038/clpt.1990.117